132 related articles for article (PubMed ID: 29448309)
21. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
Vangangelt KMH; Tollenaar LSA; van Pelt GW; de Kruijf EM; Dekker TJA; Kuppen PJK; Tollenaar RAEM; Mesker WE
Int J Cancer; 2018 Dec; 143(12):3194-3200. PubMed ID: 29978463
[TBL] [Abstract][Full Text] [Related]
24. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
26. Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
Yan D; Ju X; Luo B; Guan F; He H; Yan H; Yuan J
BMC Cancer; 2022 Oct; 22(1):1082. PubMed ID: 36271354
[TBL] [Abstract][Full Text] [Related]
27. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Petrelli NJ; Colangelo LH; Atkins JN; Seay TE; Fehrenbacher L; Goldberg RM; O'Reilly S; Chu L; Azar CA; Lopa S; Wolmark N
J Clin Oncol; 2011 Jan; 29(1):11-6. PubMed ID: 20940184
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Cunningham D; Lang I; Marcuello E; Lorusso V; Ocvirk J; Shin DB; Jonker D; Osborne S; Andre N; Waterkamp D; Saunders MP;
Lancet Oncol; 2013 Oct; 14(11):1077-1085. PubMed ID: 24028813
[TBL] [Abstract][Full Text] [Related]
30. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.
Wu J; Liang C; Chen M; Su W
Oncotarget; 2016 Oct; 7(42):68954-68965. PubMed ID: 27661111
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
32. Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study.
Ma R; Lin YL; Li XB; Yan FC; Xu HB; Peng Z; Li Y
Diagn Pathol; 2021 Dec; 16(1):116. PubMed ID: 34895284
[TBL] [Abstract][Full Text] [Related]
33. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
[TBL] [Abstract][Full Text] [Related]
35. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
[TBL] [Abstract][Full Text] [Related]
36. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
38. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Cremolini C; Marmorino F; Bergamo F; Aprile G; Salvatore L; Masi G; Dell'Aquila E; Antoniotti C; Murgioni S; Allegrini G; Borelli B; Gemma D; Casagrande M; Granetto C; Delfanti S; Di Donato S; Schirripa M; Sensi E; Tonini G; Lonardi S; Fontanini G; Boni L; Falcone A
Eur J Cancer; 2019 Mar; 109():175-182. PubMed ID: 30735919
[TBL] [Abstract][Full Text] [Related]
39. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
